Teleflex Receives FDA Clearance for the ARROW® Triple Lumen Pressure Injectable Acute Hemodialysis Catheter

WAYNE, Pa.--()--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, has announced it has received FDA 510(k) clearance to market its ARROW® Triple Lumen Pressure Injectable Acute Hemodialysis Catheter.

“To support our goal of providing the right line for the right patient at the right time, adding the ARROW® Triple Lumen Pressure Injectable Acute Hemodialysis Catheter to our hemodialysis portfolio provides options to clinicians when choosing the best catheter for their patient,” states Jay White, President, Vascular Division of Teleflex.

The ARROW® Triple Lumen Pressure Injectable Acute Hemodialysis Catheter is available in the ARROW® ErgoPack® System, helping hospitals maintain compliance with current vascular access guidelines and standards while providing maximal barrier protection against infections when inserting these lines. Teleflex is committed to partnering with healthcare facilities to reduce vascular access related complications. The ARROW® Triple Lumen Pressure Injectable Acute Hemodialysis Catheter is another example of the Teleflex commitment to this goal.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch® and Weck® – trusted brands united by a common sense of purpose.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Teleflex, the Teleflex logo, Arrow, Deknatel, Hudson RCI, LMA, Pilling, Rusch, Weck and ErgoPack are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.

© 2015 Teleflex Incorporated. All rights reserved. MC-001588

Contacts

Teleflex Incorporated
Jake Elguicze
Treasurer and Vice President, Investor Relations
610-948-2836

Release Summary

Teleflex Receives FDA Clearance for the ARROW® Triple Lumen Pressure Injectable Acute Hemodialysis Catheter

Contacts

Teleflex Incorporated
Jake Elguicze
Treasurer and Vice President, Investor Relations
610-948-2836